Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val Enrollment is underway for the sixth dose cohort of the Phase 1b dose escalation portion of the study with plans to initiate a recommended Phase 2 dose-optimization cohort as part of the study’s Phase 2 expansion in 2024 Data featured in an oral presentation at the European Society of Medical Oncology Asia Congress SAN DIEGO, Dec.

在剂量增加期间没有剂量限制性毒性的已确认的部分反应以及新的临床前数据支持有机会通过新的分次每日给药方案在更高剂量水平的Nana进一步提高疗效。该研究的第1b阶段剂量递增部分的第六剂量队列正在进行val登记，并计划启动建议的第2阶段剂量优化队列作为2024年研究第2阶段扩展的一部分，数据在12月圣地亚哥欧洲医学肿瘤学会亚洲大会的口头报告中有所体现。

04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC) showed two ongoing confirmed partial responses (PRs) at higher dose levels.

042023（GLOBE NEWSWIRE）-Viracta Therapeutics，Inc。（纳斯达克股票代码：VIRX），一家临床阶段精密肿瘤公司，专注于治疗和预防影响全球患者的病毒相关癌症，今天宣布，在复发或转移性（R/M）Epstein-Barr病毒阳性（EBV+）鼻咽癌（NPC）患者中，Nana-val（nanatinostat联合缬更昔洛韦）1b/2期临床试验的额外数据显示两个正在进行的较高剂量水平的确认部分反应（PR）。

These data were featured in an oral presentation made by A. Dimitrios Colevas, M.D., Professor of Medicine (Oncology) at the Stanford Cancer Institute, during the European Society for Medical Oncology (ESMO) Asia Congress being held in Singapore. Nana-val is the company’s all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers.

这些数据以斯坦福癌症研究所医学（肿瘤学）教授A.Dimitrios Colevas博士在新加坡举行的欧洲医学肿瘤学会（ESMO）亚洲大会期间的口头报告为特色。Nana-val是该公司针对Epstein-Barr病毒（EBV）相关癌症的全口服研究疗法。

“The initial efficacy, safety, and pharmacokinetic data from the first five dose cohorts of the Phase 1b trial in patients with recurrent or metastatic EBV-positive NPC are very encouraging,” said Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer of Viracta. “These results support the continued advancement and dose e.

Viracta首席医疗官Darrel P.Cohen博士，博士说：“1b期临床试验的前5个剂量组在复发或转移性EBV阳性NPC患者中的初始疗效，安全性和药代动力学数据非常令人鼓舞。”。“这些结果支持持续推进和剂量e。